Hopp til innhold
Bergen, Norway 20 April 2022

Islay Venture GmbH ("Islay), a company closely related to Lifecare's Chief
Scientific Officer and primary insider Prof. Dr. Dr. med Andreas Pfützner, will
subscribe 1.756.876 new shares in Lifecare AS, as part of the previously agreed
consideration from Lifecare AS to acquire Lifecare Laboratories GmbH (formely
named Pfützner Science and Health GmbH). The acquisition and considerations were
previously announced in Newsweb 27 August 2021.

Lifecare AS will issue shares in Lifecare AS equivalent to a value of EUR
300.000 EUR converted into NOK 2.856.840,- at an exchange rate of NOK 9,5228.
The amount will convert into 1.756.876 Lifecare AS new shares at a calculated
VWAP-based share price of NOK 1,626091. The share price is based on VWAP 5
consecutive trading days prior to the share purchase agreement's notarised
signature date: 27 January 2022.

Islay currently holds 843.623 shares in Lifecare AS. After the issuance of new
shares, Islay will hold a total of 2.600.499 shares in Lifecare AS.

The new shares will be issued based on board authorization granted by the
Extraordinary General Meeting of Lifecare 10 September 2021 as registered in the
company register 8 November 2021. The share issue is expected to be completed by
30 April 2022.

On this base the Lifecare board of directors has resolved to issue in total
1.756.876 new shares for an aggregated subscription price of NOK 2.856.840.
Following the issuance of the new shares, the Company will have 99.741.023
shares outstanding, each with a nominal value of NOK 0.40. Total share capital
of the Company will be NOK 39.896.409,20-. The Company's Articles of
Associations will be updated accordingly.

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on
20 April 2022 at 20:10 CET.